SNSE · Insider Trading
Sensei Biotherapeutics, Inc. Common Stock
Every open-market purchase and sale reported by SNSE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-16 | Anand Kiran Parikh | President and CEO | C | +761,428 | — |
| 2026-06-16 | Anand Kiran Parikh | President and CEO | A | +149,965 deriv. | — |
| 2026-06-16 | Stephen M. Hahn | Director | C | +44,763 | — |
| 2026-06-16 | Saira Ramasastry | Director | A | +25,000 deriv. | — |
| 2026-06-12 | Bob Holmen | Director | A | +12,500 deriv. | — |
| 2026-06-12 | Christopher Gerry | President & PEO | A | +220,000 deriv. | — |
| 2026-06-12 | Phillip B. Donenberg | Director | A | +12,500 deriv. | — |
| 2026-06-01 | Cambrian BioPharma Inc | 10%+ Owner | Sell | −25,000 | −$500.54K |
| 2026-06-01 | James Peyer | 10%+ Owner | Sell | −25,000 | −$500.54K |
| 2026-05-15 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | MIXED | +37,756 | +$1.22M |
| 2026-05-15 | MILLENNIUM GROUP MANAGEMENT LLC | 10%+ Owner | MIXED | −51,444 | −$1.59M |
| 2026-05-15 | MILLENNIUM MANAGEMENT LLC | 10%+ Owner | MIXED | +109,340 | +$2.92M |
| 2026-04-14 | Josiah Craver | PFO & PAO | A | +80,000 deriv. | — |
| 2026-04-14 | Phillip B. Donenberg | Director | A | +23,100 deriv. | — |
| 2026-02-19 | Anand Kiran Parikh | Chief Operating Officer | A | +2,198,333 deriv. | — |
| 2026-02-17 | Phillip B. Donenberg | Director | A | +1,900 deriv. | — |
| 2025-12-10 | James Peyer | 10%+ Owner | MIXED | −6,217 | −$52.05K |
| 2025-12-10 | Cambrian BioPharma Inc | 10%+ Owner | MIXED | −6,217 | −$52.05K |
| 2025-12-08 | Cambrian BioPharma Inc | 10%+ Owner | Sell | −21,295 | −$232.69K |
| 2025-12-08 | James Peyer | 10%+ Owner | Sell | −21,295 | −$232.69K |
| 2025-05-23 | Bob Holmen | Director | A | +19,000 deriv. | — |
| 2025-05-23 | Cambrian BioPharma Inc | 10%+ Owner | A | +19,000 deriv. | — |
| 2025-05-23 | Thomas G Ricks | Director | A | +19,000 deriv. | — |
| 2025-05-23 | William R Ringo | Director | A | +19,000 deriv. | — |
| 2025-05-23 | Kristian Humer | Director | A | +19,000 deriv. | — |
| 2025-05-23 | James Peyer | Director | A | +19,000 deriv. | — |
| 2025-02-26 | John Celebi | PRESIDENT AND CEO | F | −5,558 | −$2.65K |
| 2025-02-26 | Horst Edward van der | CHIEF SCIENTIFIC OFFICER | F | −2,276 | −$1.08K |
| 2025-02-14 | Horst Edward van der | CHIEF SCIENTIFIC OFFICER | A | +110,000 deriv. | — |
| 2025-02-14 | Stephanie Krebs | Chief Business Officer | A | +120,000 deriv. | — |
| 2025-02-14 | John Celebi | PRESIDENT AND CEO | A | +360,000 deriv. | — |
| 2025-02-14 | Josiah Craver | Principal Financial Officer | A | +50,000 deriv. | — |
| 2024-12-23 | Josiah Craver | Principal Financial Officer | A | +100,000 deriv. | — |
| 2024-12-23 | Horst Edward van der | CHIEF SCIENTIFIC OFFICER | A | +100,000 deriv. | — |
| 2024-12-23 | Stephanie Krebs | Chief Business Officer | A | +120,000 deriv. | — |
| 2024-12-23 | John Celebi | PRESIDENT AND CEO | A | +355,000 deriv. | — |
| 2024-06-13 | Cambrian BioPharma Inc | 10%+ Owner | A | +19,000 deriv. | — |
| 2024-06-13 | Jessie English | Director | A | +19,000 deriv. | — |
| 2024-06-13 | James Peyer | Director | A | +19,000 deriv. | — |
| 2024-06-13 | Deneen Vojta | Director | A | +19,000 deriv. | — |
| 2024-06-13 | Bob Holmen | Director | A | +19,000 deriv. | — |
| 2024-06-13 | Thomas G Ricks | Director | A | +19,000 deriv. | — |
| 2024-06-13 | Kristian Humer | Director | A | +19,000 deriv. | — |
| 2024-06-13 | William R Ringo | Director | A | +19,000 deriv. | — |
| 2024-02-16 | Erin Colgan | CHIEF FINANCIAL OFFICER | F | −3,627 | −$2.87K |
| 2024-02-16 | John Celebi | PRESIDENT AND CEO | F | −5,891 | −$4.65K |
| 2024-02-16 | Horst Edward van der | CHIEF SCIENTIFIC OFFICER | F | −2,843 | −$2.25K |
| 2023-11-02 | Stephanie Krebs | Chief Business Officer | A | +125,000 deriv. | — |
| 2023-09-13 | John Celebi | President and CEO | Buy | +500 | +$425 |
| 2023-09-11 | Erin Colgan | Chief Financial Officer | F | −10,943 | −$16.41K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Anand Kiran Parikh | President and CEO | 761,428 | $10.55M |
| James Peyer | Director | 286,601 | $3.97M |
| MILLENNIUM GROUP MANAGEMENT LLC | 10%+ Owner | 141,029 | $1.95M |
| MILLENNIUM MANAGEMENT LLC | 10%+ Owner | 131,370 | $1.82M |
| Cambrian BioPharma Inc | 10%+ Owner | 130,142 | $1.80M |
| Stephen M. Hahn | Director | 44,763 | $619.97K |
| Thomas G Ricks | Director | 17,194 | $238.14K |
| John Celebi | PRESIDENT AND CEO | 5,293 | $73.31K |
| Horst Edward van der | CHIEF SCIENTIFIC OFFICER | 2,990 | $41.41K |
| Bob Holmen | Director | 1,280 | $17.73K |
| William R Ringo | Director | 1,170 | $16.20K |
| Kristian Humer | Director | 447 | $6.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SNSE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.